Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs 10X Genomics Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.35 (market cap $162.00B), while 10X Genomics Inc trades at $80.88 (market cap $10.07B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 16.1× 10X Genomics Inc's market cap, and iShares Core MSCI Emerging Markets ETF is more actively traded (13,446,151 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and 10X Genomics Inc for 91 Days on average.
| IEMG | TXG | |
|---|---|---|
Market Cap | $162.00B | $10.07B |
Volume | 13,446,151 | 5,657,286 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $97.74 |
52-Week Low | $64.22 | $11.48 |
Typical Hold Time | 57 Days | 91 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.40, down 0.78% with bearish technical signals from moving averages while oscillators remain neutral. The emerging markets ETF has demonstrated strong performance with 35% returns over the past year according to recent analysis, though faces competition from lower-cost alternatives. Recent news highlights emerging markets attracting record capital flows as investors diversify beyond US mega-cap technology stocks.
The outlook remains cautiously optimistic given emerging markets' recent outperformance and dollar weakness, though higher expense ratios compared to competitors and concentration in technology sectors present risks. Technical indicators suggest near-term pressure with support at $79-80 levels, while fundamental strength in emerging market growth supports longer-term potential.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
